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The gut microbiota (GM) consists of resident commensals and transient microbes conveyed by the diet but
little is known about the role of the latter on GM homeostasis. Here we show, by a conjunction of
quantitativemetagenomics, in silico genome reconstruction andmetabolicmodeling, that consumption of a
fermented milk product containing dairy starters and Bifidobacterium animalis potentiates colonic short
chain fatty acids production and decreases abundance of a pathobiont Bilophila wadsworthia compared to a
milk product in subjects with irritable bowel syndrome (IBS, n528). TheGM changes parallel improvement
of IBS state, suggesting a role of the fermentedmilk bacteria in gut homeostasis. Our data challenge the view
that microbes ingested with food have little impact on the human GM functioning and rather provide
support for beneficial health effects.
T
he gut is inhabited by microbial communities that form an intimate and beneficial association with the host.
It is an open microbial ecosystem composed of resident commensals that are continuously exposed to
transient exogenous microbes originating from the diet. Many fermented foods and yoghurt in particular,
contain high quantities of live bacteria, typically up to 109 CFU/g. These foods have been major contributors to
the human diet since the Neolithic Era1, yet ourmodern understanding of the impact of food-ingested bacteria on
our resident gut microbiome remains limited. To date, a majority of studies failed to identify significant modula-
tions of the resident human gutmicrobiota upon consumption of fermented food2–6. This is likely due to the use of
methods lacking sufficient phylogenetic resolution at the species level.
During the last two decades, human gut microbiota structure has increasingly been assessed by culture-
independent methods based on 16S rRNA gene quantification or sequencing7–11. These methods can assess the
overall structure of microbial communities but remain restricted in phylogenetic identification i) to the genus or
species-subgroup levels and ii) by the availability of phylogenetically characterized 16S rDNA sequences in public
databases. High throughput DNA sequencing-based approaches have emerged as a powerful alternative to study
the complex microbial communities12. This deep sequencing permitted the construction of the first human gut
microbiota gene catalog13. Subsequently, quantitative metagenomics has achieved species-level resolution, not
only for previously known organisms but also for unknown species14–16. These technical and analytical advances
provide the tools to explore the composition andmetabolic capacity of themicrobiota with an accuracy heretofore
unattainable.
We deployed and extended these advances to identify gut microbial species modulated by a fermented milk
product (FMP) in a 4-week intervention study in subjects suffering from Irritable Bowel Syndrome (IBS) with
constipation (n528)18. IBS is a chronic functional disorder of the intestine with a prevalence of 10% to 25% and
where 67% of diagnoses are for women17.
We aimed to use a species-level metagenomic approach to identify specific members of the gut microbiome
modulated by the FMP. We found that the FMP potentiated the production of butyrate and others short chain
fatty acids (SCFA) and decreased the levels of the opportunistic pathogen, Bilophila wadsworthia. These mod-
ifications occurred in parallel with an improvement of IBS symptoms18. Metabolic reconstruction of known and
unknown species suggests potential cross-feeding involving the food-ingested bacteria and resident commensals
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Results
We administered a FMP or an acidified milk product (MP; 125 g/
serving) to subjects fulfilling the Rome III criteria for IBS with con-
stipation (IBS-C) during 4 weeks18 (Figure 1). Bacteria contained in
the FMP were Bifidobacterium animalis subsp. lactis CNCM I-2494,
Streptococcus thermophilus CNCM I-1630 Lactobacillus delbrueckii
subsp. bulgaricus CNCM I-1632 and CNCM I-1519 and Lactococcus
lactisCNCM I-1631. The consumption of the FMP improved the IBS
condition of the subjects compared to the control group (i.e abdom-
inal distension, acceleration of the oro-caecal and colonic transit
times, overall IBS symptom severity)18. In order to assess the impact
of the FMP on the gut microbiota of the enrolled subjects, we col-
lected their stools before and after the intervention, extracted and
sequenced their fecal DNA using a SOLiD v4 Next Generation
Sequencing (NGS) device.We compared the sequencing data against
the human gut microbiome catalog of 3.3 million genes13.
Genes of FMP species are detected in fecal samples. To validate the
sensitivity of the method, we verified that DNA originating from the
FMP bacterial species could be efficiently recovered in stool samples.
We complemented the human microbiome catalog with 9030 non-
redundant genes of the FMP genomes, otherwise absent, to insure an
optimummapping of the reads against the FMP genes. Abundance of
all FMP species was significantly increased in stool samples in the
FMP group at the end of the study. The low level signal detected at
baseline and in control subjects is likely due to the presence of
endogenous species phylogenetically close to the FMP species
(Figure 2 A/B). B. lactis CNCM I-2494 was the dominant FMP
species in stool, in agreement with its relatively high survival in the
upper GI tract19,20.
Endogenousmicrobial species aremodulated by the FMP. Starting
from a comprehensive gene-centric approach, we aimed to reduce
data complexity from whole genome sequencing (WGS) reads to
individual species. Our bioinformatics pipeline, summarized in
figures 1 and S1, relied on 2 key principles: i) Increase (decrease)
of a species results in enrichment (deprivation) of the abundance of
its genes in the fecal microbiome. Consequently, gene counts should
lead to identification of species modulated by the intervention. ii)
Genes of a single species should have similar co-abundance profiles
across individuals since they are physically linked on a DNA
molecule (chromosome, plasmid, phage). As a result co-abundance
based gene-clustering leads to identification of clusters of genes
corresponding to one bacterial species as already demonstrated14,15.
We identified 1320 and 641 genes as significantly over- or under-
represented after the consumption of the FMP ormilk product (MP),
respectively. We designated these FMP or MP ‘‘modulated genes’’.
Twenty seven percent of the FMP-modulated and 22% of the MP-
modulated genes could be assigned to known species by blastN
(Figure S2 A/B/C). Clustering by Spearman correlation was applied
to the 1320 and 641 modulated genes using the MetaHIT cohort to
increase statistical power and improve species assignment36.
Benchmarking against genes assigned to known species revealed
that for clusters retrieved with a Spearman correlation factor of 0.75,
97% of genes were assigned to one cognate genome (i.e. known
species) (Figure S3). This result confirms that clusters of genes iden-
tified can accurately serve as a proxy for intestinal bacterial species.
Our analysis revealed that three clusters of modulated genes were
derived from known species: Bilophila wadsworthia, Parabacteroides
distasonis and Haemophilus parainfluenzae. Eleven additional clus-
ters of genes without species-level identities were retrieved from the
1961 modulated genes (Figure S2D/E). The assignment of genes to
unknown species allowed us to increase the percentage of genes
without species-level identities for the FMP group from 27% to
51% (Figure S2A). Unknown species were assigned a number pre-
fixed with the tag ‘‘MGS,’’ for MetaGenomic Species.
Integrating both known species and MGS results in a significant
gain in statistical power through the compression of the number of
variables as compared with the full catalog of 3.3 million genes. The
identification of co-variant clusters also yields signatures that are
Figure 1 | Study design and overview of the bioinformatic pipeline used in this study.
www.nature.com/scientificreports
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more reliable than a single gene target. We computed the relative
abundance of each known or unknown species by averaging the
frequency of 50 representative genes for each species, as reported
previously36 and compared the abundances using a Wilcoxon
paired-test corrected for multiple testing. This revealed that con-
sumption of the FMP stimulated MGS126, MGS203, MGS106,
MGS109 and Bifidobacterium dentium. Three species, Parabacte-
roides distasonis, B. wadsworthia and Clostridium sp. HGF_2 were
found to be inhibited (p,0.05) (Figure 2C). In the MP group, only
two species, Haemophilus parainfluenzae and MGS204 varied sig-
nificantly (p,0.05) (Figure 2D).
Reconstitution of the genetic repertoire of unknown species. We
then attempted to extend the co-variance approach to the full catalog
of 3.3million genes in order to retrieve other genes of the FMP orMP
modulated species. A unique gene of a given cluster was used as a
‘‘prey’’ to ‘‘chase’’ the genes of the catalog co-varying with the prey at
a given threshold. Sets of co-varying genes from the full catalog were
retrieved in a step by step approach, and formed metagenomics
clusters centered around the initial modulated genes identified
above. We benchmarked this approach with 10 known species
(Table S1), and retrieved an average of 2554 genes per species with
a specificity of .95%, illustrating the applicability of this approach
for retrieving genes of unique bacterial species (Table S1, cf.
supplementary material). We applied the same procedure to the
FMP-modulated MGS and retrieved .1900 genes for all the MGS
(Figure S5A) but 2 (MGS106, MGS109), which had sub-bacteria-
sized gene repertoires and were not further investigated. Five MGS
were identified as Clostridiales including Eubacterium (MGS146),
Clostridium (MGS134), Roseburia (MGS204) and unknown genera
(MGS203, MGS126) and 2 MGS as Bifidobacterium (MGS109,
MGS106) (Table 1, Supplementary Material).
The genetic repertoire of a MGS should contain the information
needed to perform essential bacterial functions (e.g. DNA replica-
tion, peptidoglycan synthesis, protein synthesis). Essential genes
represented an average 9.5% of MGS genetic repertoires, which is
Figure 2 | The FMP and MP modulate species of the gut microbiota. (A,B) Relative abundance of the FMP-species measured in FMP (A) and MP (B)
groups at baseline and after intervention. (C,D) Relative abundance of known or unknown (MGS) species measured in FMP (C) or MP (D) groups at
baseline and after intervention. Only MGS that were significantly modulated are depicted. Statistical significance is reported by asteriks (*;p,0.05,
***;p,0.001; Wilcoxon-paired test corrected for multiple tests comparison using the Benjamini-Hochberg procedure). Results are presented using
Tukey box-and-whisker plots as quartiles (25%, median, and 75%). Outliers were illustrated as single dots as per Tukey option of the Prism Graph
software.
www.nature.com/scientificreports
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comparable to other gut commensals such as Escherichia coli and
Bifidobacterium longum (Figure S5B). By the same token, it is
expected that functions encoded byMGS should also cover themajor
metabolic pathways present in any microbial cell (i.e. carbohydrate,
lipid, amino acids and nucleic acids metabolisms). Genes of MGS
were assigned putative functions by comparing them to Cluster of
Orthologous Groups (COGs)21 using the CD-Search Tool22. Sorting
of these COGs by their hierarchical functional categories confirmed
that functions encoded by the MGS similarly cover the major meta-
bolic pathways compared to reference commensals (E. coli and B.
longum) (Figure S5C). This result was supported by the projection of
the MGS and E. coli on the global map of KEGG metabolism
(Figure 3A, Figure S6).
We concluded that we retrieved nearly complete genomes of the
FMP-modulated species, allowing further metabolic and ecological
analyses.
FMP increases potential butyrate producers. The Clostridiales are
primary butyrate producers. Our analysis revealed that MGS126,
MGS203, MGS204 and Clostridium sp. HGF2 possess the genetic
capacity to produce butyrate (Figure 3B).
In order to assess the impact of the FMP on the butyrate producing
community, we reconstituted the butyrogenic modules of the entire
human microbiome gene catalog by applying the gene-clustering
algorithm to the genes of the catalog encoding the butyrate synthesis
pathway (cf. Supplementary Methods). This procedure yielded 39
butyrogenic modules of which 30 could not be taxonomically
assigned at the species level (Figure 3C). The 9 species-assigned
modules were previously reported to belong to experimentally-con-
firmed butyrate producers Roseburia intestinalis, Roseburia inulini-
vorans, Butyriovibrio crossotus, Clostridium L2-50, Faecalibacterium
prausnitzii, Eubacterium hallii, Lachnopsiraceae bacterium 5_1_
63FAA, Coprococcus ART55/1 and Acidaminococcus intestini
D2123–25. Among the 30 non-assigned species modules, 27 belong
to the Order Clostridiales including 5 Lachnopsiraceae, 8 Clostri-
diaceae, 2 Veillonellaceae and 1 Bacteroidales. Each of these taxa is
known to have members capable of butyrate production25–28. This
result validated our approach, as we retrieved butyrogenic modules
belonging tomajor known intestinal butyrate producers. The relative
abundances of the butyrogenic modules were calculated across the
studied cohort. Module 12, among the 10 most abundant, belongs to
MGS126. Modules 44 and 20 belong to MGS203 and MGS204,
respectively. As expected, in parallel with their respectiveMGS,mod-
ules 12 and 20 were significantly increased and decreased after FMP
and MP consumption, respectively (Wilcoxon paired test; data not
shown). A trend (p,0.10) showing an increase of the module 44
(MGS203) was also observed in the FMP group, although it did
not reach statistical significance (data not shown). Intergroup com-
parisons of butyrogenic modules after the interventions indicated a
higher abundance of module 4 (Roseburia inulinivorans) in the FMP
group as compared to the MP group (p,0.05; ANCOVA without
multiple test correction; p.0.05 after Benjamini-Hochberg multiple
test correction; Figure S8).
Butyrogenic bacteria are known to produce propionate as an end
product of L-fucose degradation29. The presence of L-fucose degrad-
ing genes in the genomes of MGS126 and MGS203 might indicate a
metabolic potential to also produce propionate (Table 2).
FMP stimulates the production of SCFA in vitro. In order to fur-
ther assess the impact of the FMP on short chain fatty acid produc-
tion we used a 5-compartiment ex vivo human colonic fermenter
(SHIME H PRODIGEST)30 inoculated independently with 2
different healthy donors and kept stable for .5 weeks. We
observed that the addition of the FMP led to a significant increase
of butyrate, propionate and total SCFA, in the 3 different vessels
mimicking the ascending, transverse and descending colon condi-
tions as compared with baseline (Figure 4, Figure S7). Butyrate was
the SCFA with the largest observed increased registering an average
1.9 fold augmentation across vessels and individuals (Figure 4).
Functions encoded by FMP-modulated bacteria.Next, we reasoned
that species stimulated (or decreased) by the FMP might have
responded to the same environmental intraluminal changes trig-
gered by the ingestion of FMP bacteria. We aimed to have a better
insight on habitat type, cell cycle and energy metabolism of the FMP
modulated species by identifying shared functions of FMP-stimulated
species absent in FMP-inhibited species, and vice-versa. Available
genome information of known species and the reconstituted
genetic repertoires of MGS were used to perform comparative
genomics and identify Clusters of Orthologous Genes (COGs)21
discriminating between FMP-stimulated and inhibited species
(Table 2, TableS2).
Genes encoding pili were present in all FMP-modulated species
indicating a potential for epithelial adhesion. MGS126 and MGS203
possessed enzymes allowing utilization of L-fucose which is a mucin
derivedmonosaccharide. These 2 species also carried genes encoding
the syntheses of flagellin and spores, which have both been reported
to be involved in mucus colonization31,32. Taken together, this data
informed us on the possible adaptation of these species to a mucous
environment.
The presence of genes involved in oxidative phosphorylation (i.e.
cytochrome oxidases bd) in B. wadsworthia and P. distasonis gen-
omes indicates a shared capacity of these species to inhabit niches
where oxygen tension is low (i.e. epithelial interface).
We further investigatedwhether inhibited species shared common
features that would be absent in stimulated species. Genes encoding a
putative carbonmonoxide dehydrogenase (CODH)were found to be
present in B. wadsworthia and Clostridium sp. HGF2 genomes pre-
dicting their capacity to use carbon monoxide (CO) as an electron
donor33. Heme oxygenase is a known source of intestinal CO and its
activity has been shown to be up-regulated during intestinal inflam-
mation34. This suggests that CO utilization might be an advantage in
inflamed conditions for organisms able to use it. B. wadsworthia also
possesses the set of genes (i.e. HMP0179_00240-00243) allowing
anaerobic respiration of nitrate, a substrate that is also enriched
during inflammation35.
Table 1 | Taxonomic assignment of unknown species (MGS)
MGS Phylum Order Family Genus
109 Actinobacteria Bifidobacteriales Bifidobacteriaceae Bifidobacterium
106 Actinobacteria Bifidobacteriales Bifidobacteriaceae Bifidobacterium
146 Firmicutes Clostridiales Eubacteriaceae Eubacterium
134 Firmicutes Clostridiales Clostridiaceae Clostridium
126 Firmicutes Clostridiales Clostridiaceae/Lachnospiraceae*
204 Firmicutes Clostridiales Lachnospiraceae Roseburia
203 Firmicutes Clostridiales Clostridiaceae/Lachnospiraceae*
The assignments were based on the MEGAN package57.
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 4 : 6328 | DOI: 10.1038/srep06328 4
Discussion
Fermented foods have been a part of the human diet since,10 000
BC comprising different matrixes such as milk (i.e kefir, yoghurt,
dahi, cheese) or vegetables (i.e. nato, sauerkraut, pickles)1. Beneficial
effects of fermented milks were empirically assessed by the Nobel
Prize laureate Elie Metchnikoff in 1907 who predicted their role in
the enhanced health and longevity of Bulgarian populations36. In the
light of our increased understanding of the impact of the gut micro-
biome on host health, the question arises how food-ingested micro-
bial communities modulate the autochtonous microbiota.
The emergence of molecular tools based on the 16S rDNA gene
brought about a revolution in understanding the immense diversity
of gut microbial communities and their links with host health and
diet. However, variations of 16S rDNA sequences do not provide
Figure 3 | Metabolic reconstruction of unknown gut microbial species shows a FMP-mediated increase of potential butyrate producers. A) Projection
on KEGGmetabolic pathways of functions encoded by theMGS126 reconstructed genome (in red) using Ipath tool55. Functions of the KEGG global map
were depicted underneath. B) Presence of genes predicted to encode enzymes of the butyrate synthesis pathway (thiolase EC 2.3.1.9 (THL); b-
hydroxybutyryl-CoA dehydrogenase (BHCD; EC 1.1.1.35); crotonase (CRO; EC 4.2.1.17); butyryl-CoA dehydrogenase (BCD; EC 1.3.99.2); Electron-
Transfer Flavoprotein a and b sub-units (ETFa and ETF b; E.C. 1.5.5.1); butyrate kinase (BK; EC 2.7.2.7); butyryl-coA acetyl-coA transferase (ButCoA;
EC 2.8.3.8) among the reconstitutedClostridialesMGS. C) Abundance of butyrogenic modules of the human gutmicrobiota in the IBS cohort at baseline.
Mean and standard deviation are represented. Results are presented using Tukey box-and-whisker plots.
www.nature.com/scientificreports
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basis for species-level resolution8. Consequently, studies using 16S
gene as a phylogenetic marker and reporting unaltered gut micro-
biota upon probiotic consumption2–6 might have failed in detecting
changes of the microbiota due to the lack of species-level resolution.
Such hypothesis can be accurately studied nowwith the emergence of
novel technologies allowing species-level gut microbiota mapping.
In the current work, whole genome sequencing analysis coupled
with a gene-centric approach was used to investigate the effect of a
FMP on the human gut microbiota at the species-level resolution.
Initially, only 27% (356 of 1320) of genes modulated by the FMP
could be assigned to known species; illustrating the limited repres-
entation of bacterial commensals in publicly available genome
databases. By employing gene clustering methodologies14–16, the spe-
cies-level assignment of FMP-modulated genes was increased to
51%. This clustering algorithm was further used to reconstitute the
bacterial gene repertoires of the unknown species used for compa-
rative genomics.
Upon FMP consumption, two previously uncharacterized butyr-
ate producers MGS203 and MGS126 were increased. MGS126 was
among the 10 most abundant butyrogenic bacteria of the human gut
microbiota. This argues for a positive effect of the FMP on the net
production of butyrate in the colon. Importantly, this hypothesis was
supported by our in vitro results obtained with the SHIMEH fermen-
ter and in a mouse model of intestinal inflammation37. MGS203 and
MGS126 were likely stimulated by the FMP-mediated increase of
Bifidobacterium species resulting in a higher production of acetate
and lactate, used by butyrate producers23,38.
Recent studies have shown that B. wadsworthia and P. distasonis
were increased in western diet enriched in saturated animal fat39,40 or
RS4, a resistant starch used in processed foods41, respectively.
Although an unlikely potential effect of dietary changes between
groups cannot be excluded to explain the decrease of these 2 species
in the FMP group, we privileged the more likely hypothesis that the
FMP modulated-species responded to FMP-mediated signals. We
thus reasoned that species inhibited in the FMP group shared com-
mon metabolic pathways that we investigated by comparative
genomics.
B. wadsworthia is a gram negative d-Proteobacteria first isolated
from an appendicitis patient and is often associated with inflamed
and/or infected clinical samples42. Its genetic potential to utilize the
known inflammation-associatedmetabolites like nitrate and possibly
carbon monoxide, suggests that it can be fueled by host-derived
Table 2 | Selected shared functions of FMP-modulated species
Pathways/Functions
FMP-stimulated species* FMP-inhibited species*
MGS126 MGS203 B. dentium B. wadsworthia P. distasonis C. HGF2
Carbohydrate metabolism
Mucin derived monosaccharides degrading enzymes (fucose,
mannose, N-acetylglucosamine)
6 6
Plant polysaccharides degrading enzymes (cellobiose,
starch, arabinan)
9 8 5 2 1 1
Motility, structural structures
Tad Pili 1 2 2 3 2 2
Spore formation 21 21
Flagellin synthesis 18 18
LPS production 7 7
Energy and metabolism
C4 TRAP transport 3 3 3
NiFe hydrogenases 7 7
Dissimilatory sulfite reductase 1 1
CO assimilation 3 3
Oxydative phosphorylation 7 7 1
*Number of COG/per genome associated to pathway/functions.
Figure 4 | The FMP stimulates the production of butyrate by human colonic microbiota in vitro. The SHIME colonic fermenter mimicking conditions
of the acending, transverse and descending colons (reference 30) was inoculated with fecal microbiota of 2 healthy human donors (black and grey
columns) and after 2 week (C1 & C2 time points) exposed to FMP during 3 weeks (T1, T2 and T3 time points). Mean fold changes between control and
treatment periods are reported when statistical significance was met. n.s: non-significant, *** (p,0.001, ANOVA).
www.nature.com/scientificreports
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products enriched during inflammation, similarly to other patho-
bionts (i.e. Salmonella enterica)35. By the same token, the carbon
monoxide dehydrogenase genes of another FMP-modulated species,
Clostridium sp. HGF_2, suggests that it could also take advantage of
intestinal inflammation34. Both B. wadsworthia and Clostridium sp.
HGF_2 are decreased by the FMP, which could thus have an anti-
inflammatory effect as observed in the mouse model of colitis37.
The FMP-induced changes in the GM paralleled improvement of
IBS condition in our cohort, suggesting a role of the FMP-modulated
species in the amelioration of the clinical parameters18. This hypo-
thesis is compatible with the observations that i) butyrate, known to
improve intestinal motility43,44 and visceral sensitivity45, is underpro-
duced by IBS-C gut microbiota compared to healthy controls46 and
ii) B. wadsworthia is pro-inflammatory40 and produces sulfide which
is toxic47 and nociceptive48.
The MP has reduced effects on gut microbiota compared to the
FMP which is consistent with the absence of an active microbial
community in this product. Only 2 species, H. parainfluenzae and
the Clostridiales MGS204, were shown to be modulated (i.e.
decreased) upon the MP intervention. Changes observed in the
MP group might originate from a natural variation of the gut com-
munity reported to be higher in IBS compared to healthy controls49.
Alternatively, it is also possible that the MP induced changes in the
gut microbiota. Since H. parainfluenzae is a c-proteobacteria con-
sidered as a gut pathogen and previously associated with IBS in
children50, MP-mediated changes might therefore account for the
reported MP placebo effect18,51.
In conclusion, our study sheds light on the potential of the bacteria
conveyed by fermented milks to stimulate synthesis of beneficial
metabolites and decrease abundance of pathobionts. These modifi-
cations can potentially improve health and are thus of importance for
public health recommendations in western countries. It indicates
that the role of food-ingested bacteria in gut homeostasis has been
under-estimated, possibly because ofmethodological limitations that
can, today, be overcome. Elucidation of the intricate links between
food ingestedmicrobes and human symbionts can thus be addressed.
Methods
Subjects and study design. The study18, was a single centre, randomized, double-
blind, controlled, parallel-group design including women (aged 20–69 years),
fulfilling the Rome III criteria for IBS-C. Subjects were asked to not consume
probiotic-containing products or fermented dairy products. There was no dietary
record. After an 11-day wash-out period, 32 subjects (Per Protocol) consumed (125 g/
serving) twice a day either the FMP (n517) or an acidifiedmilk product (MP) (n515)
for 4 weeks. Out of 64 stools collected within the PP population, 56 samples (n526
and 30, for FMP andMP, respectively) passed DNA quality control and were used for
further analyses. Other dairy products and probiotics were excluded from the diet.
Study products. The FMP contained 1.25 3 1010 colony forming units per serving
(cfu/serving) Bifidobacterium animalis subsp. lactis (strain number I-2494 in the
French National Collection of Cultures of Micro-organisms (CNCM), Paris, France),
1.2 3 109 cfu/serving of Streptococcus thermophilus (CNCM I-1630) Lactobacillus
delbrueckii subsp. bulgaricus (CNCM I-1632 and CNCM I-1519) and Lactococcus
lactis (CNCM I-1631). The MP was an acidified milk product with low lactose
content. FMP and MP were provided by Danone Research (Palaiseau, France).
Stool collection, storage, fecal DNA extraction and sequencing. Stool samples were
collected before and after the 4-week consumption period. Immediately after
defecation, a fecal sample was collected and stored in RNAlater solution (Ambion).
The fecal suspension was homogenized and the volume of RNAlater was adjusted to
achieve a final fecal dilution of 1510 (wt/vol). 200 ml of the 10-fold dilution were
added to 1 ml of Phosphate Buffered Saline (Sigma-Aldrich) and centrifuged for
5 min at 5,000 3 g. The supernatant was discarded and the fecal pellet stored at
280uC. Fecal DNA was extracted as previously described52. DNA samples were
sequenced on a SOLiD v4 NGS (Life Technologies) following the standard protocol
for fragment libraries. The raw SOLiD read data was deposited in the EBI European
Nucleotide Archive under the accession number PRJEB7171.
Identification of the species modulated by the interventions. Our bioinformatics
pipeline, summarized in the Figure S1, aimed to decrease data complexity starting
from reads and identify bacterial species modulated by the intervention. In brief, 50-
bases tags (reads) were generated with SOLiD v4 sequencer, mapped on theMetaHIT
3.3 million genes catalog and genes count profiles were generated for each individual.
Genes potentially modulated upon the intervention (intra-group analysis) were
identified with a Kruskall-Wallis test, clustered and assigned to known or unknown
species. Relative abundance of a given species was computed by averaging the
frequency of 50 genes belonging to the species. DNA from the samples (n528) was
sequenced with a SOLiD v4 sequencer and an average of 3.97 3 107 50-bases tags
(reads) per sample were generated and mapped on the MetaHIT 3.3 million genes
catalog13 (average 1.713 107 reads/sample; S.D.1/2 7.793 106) usingMETEOR, an
in-house software53. Only those tags that mapped uniquely (univocally) to a single
gene and to the exclusion of FMP genomes were retained (1.303 107 reads/sample;
S.D.1/2 5.883 106). To quantify FMP species, the catalog of 3.3 million genes was
complemented by the non-redundant genes (n59030) of the FMP genomes4,54. Genes
count profiles were generated for each individual and genes significantly enriched or
depleted upon the intervention (intra-group analysis) were identified with a Kruskall-
Wallis test. Clusters of genes or species counting less than 9 (or 5) genes in the FMP
(or MP) group were disregarded since these clusters are more likely to have resulted
from random variations (see supplementary material).
Quantification of mapped reads to the annotated reference was used to identify
genes belonging to the endogenous microbiota that were significantly modulated
upon intervention. AMann-Whitney test was performed for FMP andMP groups to
identify genes over or under represented after intervention compared to baseline.
These are subsequently referred to as ‘‘modulated genes.’’ 1320 and 641 modulated
genes were identified for FMP and MP, respectively.
Spearman correlation coefficients were calculated for all gene pairs of this set, using
gene abundance as a variable. Clusters of genes were defined as co-varying gene
groups at 0.75 spearman correlation threshold. To augment the statistical power of
the clustering analysis, we used the gene abundance matrix of 292 individuals from
the MetaHIT consortium (Metahit cohort)15. Genes were assigned to a species at a
threshold of 95% identity over 90% of the sequence by blastN14.
The genetic repertoire of unknown species was reconstituted through comparison
of this study’s gene clusters and the co-variation within the 3.3 million gene catalog
across theMetaHIT cohort15. Functions for each clustered or reference genome genes
were predicted using COG and/or NOG assignments. When available, COG
assignment was performed using the BatchWeb CD-Search online tool (http://www.
ncbi.nlm.nih.gov/Structure/bwrpsb/bwrpsb.cgi). Predicted functions were projected
on KEGG metabolic pathways using the Ipath software55 and compared to essential
genes identified in the model organism Bacillus subtilis56. When species-level tax-
onomy could not be assigned, higher taxonomic levels were assigned using
MEGAN57. Relative abundance was computed as the average frequency of 50 ran-
domly selected genes of a species.Wilcoxon paired test, corrected formultiple tests by
the Benjamini-Hochberg procedure, was used to test the significance of the FMP or
MP effects.
Butyrate producers of the human gut microbiome. Genes involved in butyrate
production from Roseburia intestinalis or Coprococcus eutactus25 were used as
references to retrieve homologs present in the human gut microbiome catalog by
using a bi-directional BlastP. Such genes were re-organized into co-varying clusters,
hereafter called butyrate modules, which belong to unique species (cf supplementary
material). Relative abundance of the butyrate modules was calculated as the mean of
the relative abundance of the genes composing the module. Wilcoxon paired test was
used to test the statistical significance of the variation upon interventions (intragroup
analysis). For intergroup comparisons, a one-way ANCOVA (Analysis of Co-
Variance) was used on the change from baseline for each butyrate module with the
group as factor. The relative abundance at baseline was considered as covariate. A
Benjamini-Hochberg multiple testing correction was applied to control the False
Discovery Rate.
FMP increases SCFA production in an in vitro colonic fermentation system. In
vitro colonic fermentation model (SHIMEH (Prodigest, Belgium)) mimicking the
adult gastro-intestinal tract was used to assess the impact of FMPonproduction of gut
microbial derived SCFA58. The system was inoculated with fecal sample from healthy
adults (n52). After two-week stabilization period, 50 g of FMPwas added daily to the
stomach compartment during 3 weeks. The 3 vessels mimicking the ascending,
transveral and descending colons were sampled 3 times a week. Concentrations of
acetic acid, propionic acid, butyric acid weremeasured by liquid gas chromatography.
A two-way ANOVA (Analysis of Variance) was used to evaluate the impact of FMP
consumption on the production of SCFA. The first factor was the period of treatment
and the second was the week of sampling nested in the period treatment. Tukey-
Kramer post-hoc tests were used to determine which comparisons were significantly
different if needed. Normality of residuals and homogeneity of variance were checked
to validate ANOVA hypothesis. When the hypothesis of homogeneity of variance
between groups was violated, the variance by week was used instead of a pooled
variance to allow the use of ANOVA.
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